Article
Acquired resistance to imatinib and secondary KIT exon 13 mutation in gastrointestinal stromal tumour.
Oncology reports - 1 Jul 2006
Bertucci François, Goncalves Anthony, Monges Geneviève, Madroszyk Anne, Guiramand Jérome, Moutardier Vincent, Noguchi Tetsuro, Dubreuil Patrice, Sobol Hagay
Abstract excerpt
Gastrointestinal stromal tumours (GISTs) are the most common mesenchymal tumours of the gastrointestinal tract. Most of them have an activating mutation of KIT or PDGFRalpha tyrosine-kinase receptors. Imatinib is a selective tyrosine-kinase inhibitor of ABL, KIT and PDGFR, and provides a clinical benefit in about 85% of patients with advanced GIST. Unfortunately, secondary resistance following initial responses...
Topics
Join the communities discussing this publication.